Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 61, Issue 12, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01052-17
Keywords
cefepime; tazobactam; pharmacokinetics-pharmacodynamics
Categories
Funding
- GlaxoSmithKline, Middlesex, United Kingdom
- Achaogen Inc.
- AiCuris GmbH
- Arsanis Inc.
- Cellceutix Corporation
- Cempra Pharmaceuticals
- Cidara Therapeutics Inc.
- Contrafect Corporation
- Debiopharm International SA
- Entasis Therapeutics
- Geom Therapeutics, Inc.
- GlaxoSmithKline
- Horizon
- Insmed Inc.
- Kalyra Pharmaceuticals
- Medicines Company
- Meiji Seika Pharma Co., Ltd.
- Melinta Therapeutics
- Merck Sharp Dohme
- Nabriva Therapeutics
- Naeja RGM Pharmaceuticals Inc.
- NuCana Biomed
- Paratek Pharmaceuticals
- Pernix Therapeutics
- Polyphor Ltd.
- Roche Bioscience
- Shionogi, Inc.
- Sofinnova Ventures, Inc.
- Spero Therapeutics
- Theravance Biopharma Pharmaceutica
- Tetraphase Pharmaceuticals
- VenatoRx
- Wockhardt Ltd.
- Zavante Therapeutics
- Allecra Therapeutics
- AstraZeneca
- Basilea Pharmaceutica
- BSAC
- Meiji Seika Pharma Co.
- Rokitan GmbH
- VenatoRx Pharmaceuticals
- Astellas Pharma
- Cardiome Pharma Corporation
- Cepheid Inc.
- Nordic Pharma
- Henry Stewart Talks
Ask authors/readers for more resources
We previously demonstrated that for tazobactam administered in combination with ceftolozane, the pharmacokinetic-pharmacodynamic (PK-PD) index that best described tazobactam efficacy was the percentage of the dosing interval that tazobactam concentrations were above a threshold (% T > threshold). Using data from studies of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs), a relationship between tazobactam % T > threshold and reduction in log(10) CFU/ml from baseline, for which the tazobactam threshold concentration was the product of the isolate's ceftolozane-tazobactam MIC value and 0.5, was identified. However, since the kinetics of cephalosporin hydrolysis vary among ESBLs and compounds, it is likely that the translational relationship used to derive the tazobactam threshold concentration varies among enzymes and compounds. Using a one-compartment in vitro infection model, the PK-PD of tazobactam administered in combination with cefepime was characterized, and a translational relationship across ESBL-producing Enterobacteriaceae was developed. Four clinical isolates, two Escherichia coli and two Klebsiella pneumoniae isolates, known to produce CTX-M-15 beta-lactamase enzymes and displaying cefepime MIC values of 2 to 4 mg/liter in the presence of 4 mg/liter tazobactam, were evaluated. Tazobactam threshold concentrations from 0.0625x to 1x the tazobactam-potentiated cefepime MIC value were considered. The threshold that best described the relationship between tazobactam % T > threshold and change in log10 CFU/ml from the baseline at 24 h was the product of 0.125 and the cefepime-tazobactam MIC (R-2 = 0.813). The magnitudes of % T > threshold associated with net bacterial stasis and a 1-log(10) CFU/ml reduction from baseline at 24 h were 21.9% and 52.8%, respectively. These data will be useful in supporting the identification of tazobactam dosing regimens in combination with cefepime for evaluation in future clinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available